CHRO vs. GENE, BCDA, ONVO, IKT, SRNE, COEP, TTNP, PALI, CELZ, and FRTX
Should you be buying Chromocell Therapeutics stock or one of its competitors? The main competitors of Chromocell Therapeutics include Genetic Technologies (GENE), BioCardia (BCDA), Organovo (ONVO), Inhibikase Therapeutics (IKT), Sorrento Therapeutics (SRNE), Coeptis Therapeutics (COEP), Titan Pharmaceuticals (TTNP), Palisade Bio (PALI), Creative Medical Technology (CELZ), and Fresh Tracks Therapeutics (FRTX). These companies are all part of the "biological products, except diagnostic" industry.
Chromocell Therapeutics (NYSE:CHRO) and Genetic Technologies (NASDAQ:GENE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, community ranking, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.
In the previous week, Genetic Technologies had 3 more articles in the media than Chromocell Therapeutics. MarketBeat recorded 4 mentions for Genetic Technologies and 1 mentions for Chromocell Therapeutics. Genetic Technologies' average media sentiment score of 0.41 beat Chromocell Therapeutics' score of 0.00 indicating that Genetic Technologies is being referred to more favorably in the news media.
Genetic Technologies received 161 more outperform votes than Chromocell Therapeutics when rated by MarketBeat users.
78.0% of Chromocell Therapeutics shares are held by institutional investors. Comparatively, 0.6% of Genetic Technologies shares are held by institutional investors. 6.5% of Genetic Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Chromocell Therapeutics has higher earnings, but lower revenue than Genetic Technologies.
Summary
Genetic Technologies beats Chromocell Therapeutics on 5 of the 6 factors compared between the two stocks.
Get Chromocell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CHRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CHRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chromocell Therapeutics Competitors List
Related Companies and Tools
